."Biotech innovation accelerates cancer diagnosis in startup strategy."

Manasi Khasnis, deeply impacted by her father's battle with interstitial lung disease and dissatisfied with existing diagnostic methods, embarked on a mission to innovate in the field of medical diagnostics. Her father's passing, despite medical intervention, fueled her resolve to address the shortcomings she observed. Alongside her co-founders, Snahlalta Singh and Atharva Joshi, each bringing expertise from prestigious institutions and diverse backgrounds in science and engineering, she sought to leverage their combined experience to pioneer advancements in cancer detection.

Driven by the alarming statistics of cancer-related fatalities in India, they specifically targeted the development of more effective biomarkers for detecting lung cancer. Their initiative stemmed from a belief that current diagnostic tools in this critical area are inadequate, motivating them to apply their knowledge and skills to make a tangible difference.

Through their collective academic backgrounds—Manasi's PhD and research experience, Snahlalta's doctorate and post-doctorate studies, and Atharva's engineering proficiency—they aimed to fill the gap in the market with innovative technologies. Their startup's genesis was rooted in a shared vision to transform the landscape of medical diagnostics, beginning with addressing the pressing need for improved cancer detection methods, spurred by personal loss and professional determination.